Pramipexole and Ropinirole for Parkinson's Disease
Pramipexole (Mirapex - Pharmacia & Upjohn) and ropinirole (Requip - SmithKline Beecham), two new dopamine agonists, have been approved by the US Food and Drug Administration (FDA) for treatment of both early (without levodopa) and advanced (with levodopa) Parkinson's disease. Bromocriptine (Parlodel) and pergolide (Permax) are older dopamine agonists marketed in the USA for adjunctive use with levodopa....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Pramipexole and Ropinirole for Parkinson's Disease
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1014
Article Code: 1014c
Date: November 21, 1997
Volume: 39
Pages: 109-110
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1014
Article Code: 1014c
Date: November 21, 1997
Volume: 39
Pages: 109-110
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)